证券代码：002755 证券简称：奥赛康 公告编号：2025-024 北京奥赛康药业股份有限公司 第七届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 北京奥赛康药业股份有限公司（以下简称"公司"）第七届监事会第二次会议 于 2025 年 4 月 15 日以电子邮件、专人送达的方式通知各位监事，会议于 2025 年 4 月 25 日以现场会议的方式在南京江宁科学园科建路 699 号 A 楼 3102 会议 室召开。本次会议应到监事 3 人，实到监事 3 人。本次会议符合《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）等法律、行政法规、部门规章、规范性文件和《公司章程》的相关规 定。 会议由监事会主席陈靖先生主持，经与会监事认真审议，一致形成如下决议： 一、审议通过《关于公司 2024 年度监事会工作报告的议案》 表决结果：3 票同意，0 票反对，0 票弃权。 表决结果：3 票同意，0 票反对，0 票弃权。 本议案尚需提交公司 2024 年年度股东大会审议。 经审核，监事会认为： ...

一、审议通过《关于公司 2024 年度总经理工作报告的议案》 表决结果：9 票同意，0 票反对，0 票弃权。 二、审议通过《关于公司 2024 年度董事会工作报告的议案》 表决结果：9 票同意，0 票反对，0 票弃权。 公司第六届董事会独立董事分别向董事会提交了《2024 年度独立董事述职 报告》，并将在公司 2024 年年度股东大会上述职。 本议案尚需提交公司 2024 年年度股东大会审议。 证券代码：002755 证券简称：奥赛康 公告编号：2025-029 北京奥赛康药业股份有限公司 第七届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 北京奥赛康药业股份有限公司（以下简称"公司"）第七届董事会第二次会议 于 2025 年 4 月 15 日以电子邮件、专人送达的方式通知各位董事，会议于 2025 年 4 月 25 日以现场会议的方式在南京江宁科学园科建路 699 号 A 楼 3102 会议 室召开。本次会议应到董事 9 人，实到董事 9 人。公司监事、高级管理人员代表 列席了会议。本次会议符合《中华人民共和国公司法》（以下简称" ...

证券代码：002755 证券简称：奥赛康 公告编号：2025-026 北京奥赛康药业股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 一、审议程序 监事会认为：公司 2024 年度利润分配预案符合中国证监会《上市公司监管 指引第 3 号——上市公司现金分红》及《公司章程》等有关规定关于利润分配的 要求，充分考虑了公司经营状况、未来发展需要以及股东投资回报，兼顾了投资 者的利益和公司持续发展的资金需求，符合公司和全体股东的利益，同意该预案。 监事会以 3 票同意，0 票反对，0 票弃权，审议通过《关于公司 2024 年度利 润分配预案的议案》。 二、2024 年度利润分配预案的基本情况 （一）基本情况 1、分配基准：2024 年度 2、经立信会计师事务所（特殊普通合伙）审计，2024 年度公司合并报表实 现归属于上市公司股东的净利润 160,294,273.52 元，母公司净利润-14,177,685.68 元，提取法定盈余公积金 0 元，加上期初未分配利润 149,482,529.37 元，期末母 公司可供股 ...

Financial Performance - The company's operating revenue for 2024 reached ¥1,777,641,912.11, representing a 23.15% increase compared to ¥1,443,459,608.66 in 2023[6]. - The net profit attributable to shareholders was ¥160,294,273.52, a significant turnaround from a loss of ¥148,529,759.12 in 2023, marking a 207.92% improvement[6]. - The cash flow from operating activities showed a remarkable increase to ¥411,357,064.57, compared to a negative cash flow of ¥26,568,449.33 in 2023, reflecting a 1,648.29% change[6]. - The basic earnings per share improved to ¥0.17 from a loss of ¥0.16 in the previous year, indicating a 206.25% increase[6]. - Total assets at the end of 2024 were ¥4,047,628,524.03, up 14.86% from ¥3,523,881,824.92 at the end of 2023[6]. - The total operating revenue for 2024 reached ¥1,777,641,912.11, representing a year-on-year increase of 23.15% from ¥1,443,459,608.66 in 2023[100]. - The pharmaceutical manufacturing sector accounted for ¥1,740,593,177.32, or 97.92% of total revenue, with a year-on-year growth of 21.75%[100]. - The revenue from the anti-infection product line was ¥493,917,014.16, showing a significant increase of 74.94% compared to ¥282,340,046.29 in 2023[102]. Dividend Distribution - The company plans to distribute a cash dividend of 1.20 CNY per 10 shares to all shareholders, based on a total of 928,160,351 shares[6]. - The total cash dividend represents 100% of the distributable profit of RMB 135,304,843.69 for the reporting period[190]. Research and Development - The company is actively engaged in research and development of new drugs, aiming to enhance its product portfolio[14]. - The company has submitted a total of 560 patent applications, including 349 invention patents in China and 52 PCT applications[53]. - The company has 186 valid patents, with 136 being invention patents in China, and 70% of these are high-value patents[54]. - R&D expenses for the reporting period amounted to ¥353,929,225.06, with capitalized R&D costs of ¥177,324,131.85[55]. - The company is focusing on the rapid sales growth of its anti-infection and chronic disease products, which has driven revenue growth and improved profitability[56]. - The company has established a comprehensive R&D, production, and commercialization system, enhancing its core competitiveness[57]. - The company is focusing on the development of innovative drugs and high-barrier complex formulations, with a total of 42 ongoing research projects, including 10 key innovative drugs in clinical research[51]. Product Development and Innovation - The company has developed China's first domestically produced proton pump inhibitor injection, expanding its therapeutic areas to include digestion, oncology, anti-infection, and chronic diseases[40]. - The company reported significant advancements in its product line, including the introduction of new injectable formulations for treating gastrointestinal and oncology conditions[44]. - The company has launched multiple oncology products, including Lenvatinib capsules for unresectable hepatocellular carcinoma and Palbociclib capsules for HR-positive, HER2-negative breast cancer[45]. - The company is expanding its market presence with innovative therapies that target specific genetic mutations in cancer patients, enhancing treatment personalization[44]. - The company is actively pursuing research and development initiatives to enhance its product portfolio and address unmet medical needs in various therapeutic areas[44]. Market and Competitive Landscape - The competition in the generic drug market intensified, with over 800 generic drugs passing or being deemed to have passed the consistency evaluation in 2024[32]. - The company is actively seeking international cooperation opportunities to enhance its global pipeline, with cross-border technology licensing transactions reaching new highs in 2024[31]. - The company is exploring market expansion opportunities in both domestic and international markets for its oncology and anti-infective products[45]. Corporate Governance and Management - The company has established a comprehensive corporate governance structure, enhancing operational efficiency and decision-making processes[156]. - The company maintains complete independence in business operations, personnel, assets, institutions, and finances from its controlling shareholders[157]. - The company has an independent financial department and internal audit team, ensuring a standardized financial management system[163]. - The company actively respects and protects the rights of stakeholders, promoting balanced interests among shareholders, employees, and society[156]. Quality Control and Compliance - The company emphasizes the importance of compliance with national drug production standards to ensure product quality[12]. - The company is implementing strict quality management measures to comply with new regulations and enhance its quality management system, ensuring product quality remains industry-leading[138]. - The company emphasizes quality control in its production processes, particularly for injectable products, and is committed to maintaining compliance with GMP standards[142]. Future Outlook - Future outlook includes potential expansion into new markets and the development of innovative products[6]. - The company has outlined potential risks in its future development outlook, urging investors to remain aware of these risks[6]. - By 2025, the company aims to enhance its competitive advantage through technology innovation, efficiency improvement, and cost advantages, focusing on unmet clinical needs for R&D[134].

Financial Performance - The company's revenue for Q1 2025 was ¥508,555,172.17, representing a 13.39% increase compared to ¥448,492,136.86 in the same period last year[5]. - Net profit attributable to shareholders increased by 73.50% to ¥54,730,335.25 from ¥31,544,742.35 year-on-year[5]. - The net profit after deducting non-recurring gains and losses rose by 86.93% to ¥43,997,226.18 compared to ¥23,536,136.49 in the previous year[5]. - The company reported a net profit margin improvement, with net profit increasing due to higher operating revenue and controlled costs[17]. - The net profit for the current period is 51,027,030.36, compared to 26,431,563.79 in the previous period, representing a growth of approximately 93.3%[18]. - The company's total profit for the current period is 51,772,395.44, compared to 28,800,104.97 in the previous period, showing an increase of about 80%[18]. - Basic and diluted earnings per share for the current period are both 0.06, compared to 0.03 in the previous period, reflecting a 100% increase[18]. Assets and Liabilities - The company's total assets increased by 4.97% to ¥4,248,993,672.56 from ¥4,047,628,524.03 at the end of the previous year[5]. - Current assets totaled ¥2,776,467,117.38, up from ¥2,568,164,247.66, indicating an increase of 8.1%[14]. - Non-current assets slightly decreased to ¥1,472,526,555.18 from ¥1,479,464,276.37, a decline of 0.5%[15]. - Total liabilities rose to ¥1,023,615,507.15 from ¥905,387,149.91, marking an increase of 13.0%[15]. - The company's equity attributable to shareholders increased to ¥3,145,015,100.10 from ¥3,062,651,954.20, a growth of 2.7%[16]. Cash Flow - The cash flow from operating activities decreased by 4.99% to ¥188,485,376.51 from ¥198,390,225.98 year-on-year[5]. - Operating cash flow net amount is 188,485,376.51, slightly down from 198,390,225.98 in the previous period, reflecting a decrease of approximately 4.6%[19]. - Cash flow from investment activities shows a net outflow of -412,744,811.32, compared to -50,456,332.08 in the previous period, indicating a significant increase in cash outflow[19]. - The company received cash from sales of goods and services totaling 578,669,629.09, an increase from 484,724,987.26 in the previous period, representing a growth of approximately 19.5%[19]. - The company’s cash inflow from financing activities is 47,000,000.00, significantly higher than 10,000,000.00 in the previous period, marking a 370% increase[20]. Operating Performance - Total operating revenue for the current period reached ¥508,555,172.17, an increase of 13.4% compared to ¥448,492,136.86 in the previous period[17]. - Total operating costs amounted to ¥467,198,066.18, up from ¥429,181,894.86, reflecting a growth of 8.8%[17]. - Research and development expenses were ¥59,006,421.58, a decrease of 7.9% from ¥63,512,044.42 in the previous period[17]. Intangible Assets and Government Support - The company reported a significant increase in intangible assets by 249.65% to ¥511,688,370.51, attributed to the successful launch of innovative drugs[9]. - The company received government subsidies amounting to ¥5,362,520.04, which are closely related to its normal business operations[6]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,819[11]. - Cash and cash equivalents decreased to ¥1,126,351,078.05 from ¥1,411,460,031.75, a decline of 20.1%[14]. - Cash and cash equivalents at the end of the period amount to 1,110,415,439.12, down from 1,153,337,238.95 in the previous period, a decrease of about 3.7%[20]. Comprehensive Income - The total comprehensive income for the current period is 52,672,280.11, up from 24,531,226.53 in the previous period, indicating an increase of about 114.5%[18]. - The company reported other comprehensive income after tax of 1,645,249.75, compared to -1,900,337.26 in the previous period, indicating a turnaround in this area[18].

SmartKine 平台：全球领先的细胞因子前药技术平台。SmartKine 平台有望解决细胞因子给药困难，在 有效地延长药物的半衰期、减少全身毒副作用、同时又能够实现肿瘤部位的选择性激活。基于该平台孵 化的研发管线中，细胞因子前药ASKG315、ASKG915 已进入临床阶段，另有多个分子处于早期开发及 筛选阶段。 盈利预测。我们预计公司2024-26 年归母净利润分别为1.65/1.97/2.42 亿元，分别同比增长 210.9%/19.9%/22.7%。我们认为公司创新管线上市开始逐步放量，同时仿制药业务集采影响逐步出清。 参考可比公司，我们给予公司2025年P/S 9-11 倍，合理价值区间18.88-23.07 元，合理市值区间175.21- 214.15亿元，给予"优于大市"评级。 风险提示。研发不及预期风险，监管要求变化风险，产品销售不及预期风险。 奥赛康是一家创新与研发驱动的医药制造企业。公司始终坚定解决国人临床用药的可及性、先进性和可 持续性的理想。公司的首个产品即为中国第一支质子泵抑制剂（PPI）注射剂——奥西康。30 年以来， 公司药物治疗领域已覆盖消化、抗肿瘤、抗感染、慢性病四大领域， ...

[Table_MainInfo] 公司研究/医药与健康护理 证券研究报告 奥赛康（002755）公司研究报告 2025 年 04 月 01 日 [Table_InvestInfo] 投资评级 优于大市 首次 覆盖 股票数据 | 04[Table_StockInfo 月 01 日收盘价（元）] | 19.73 | | --- | --- | | 52 周股价波动（元） | 8.33-19.80 | | 总股本/流通 A 股（百万股） | 928/928 | | 总市值/流通市值（百万元） | 18313/18312 | | 市场表现 | | [Table_QuoteInfo] -18.14% 2.86% 23.86% 44.86% 65.86% 2024/4 2024/7 2024/10 2025/1 奥赛康 海通综指 | 沪深 300 对比 | 1M | 2M | 3M | | --- | --- | --- | --- | | 绝对涨幅（%） | 37.5 | 43.1 | 55.2 | | 相对涨幅（%） | 37.6 | 41.2 | 56.4 | | 资料来源：海通证券研究所 | | | | 奥赛康是 ...

北京奥赛康药业股份有限公司 在 2025 年欧洲肺癌大会公布创新药利厄替尼用于 非小细胞肺癌治疗长期随访数据的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 北京奥赛康药业股份有限公司（以下简称"公司"）的全资子公司江苏奥赛康 药业有限公司于 2025 年 3 月 26 日至 29 日在 2025 年欧洲肺癌大会（ELCC）上 以壁报形式，公布创新药利厄替尼用于 EGFR T790M 突变阳性局部晚期或转移 性非小细胞肺癌（NSCLC）治疗的长期随访数据，相关情况如下： 一、壁报内容概要 证券代码：002755 证券简称：奥赛康 公告编号：2025-022 壁报标题：利厄替尼用于 EGFR T790M 突变阳性局部晚期或转移性非小细 胞肺癌治疗的长期随访数据：一项多中心、单臂、2b 临床研究（Long-term Follow- up of Limertinib (ASK120067) in Patients with Locally Advanced or Metastatic EGFR T790M NSCLC: A multicentre, singl ...

司，这些公司可能会因业绩超预期而获得阿尔法收益。例如，上周安吉斯年报 超预期大涨。 在创新药方面，我们关注一些具有潜力的大品种股票，如奥赛康、 新诺威、白癜风治疗公司潘玉康等。这些公司在各自领域内都有显著优势，并 且有望在未来获得更高估值。 医药行业中有哪些值得关注的投资标的？ 我们推荐以下几个值得关注的投资标的： 奥赛康 20250309 摘要 Q&A 当前医药行业的市场行情和主要趋势是什么？ 目前医药行业的市场行情表现出一定的波动性。上周 A 股和 H 股的医药板块整 体跑输大盘指数，但从成交量来看，A 股医药板块成交量约为 4%，虽然不高， 但结构上非常活跃。特别是 AI 医疗领域和创新药物领域表现突出。例如，商务 部禁止英美娜出口测序仪，带动了测试和诊断相关公司的上涨。此外，一些二 线创新企业如热情、一品红、奥赛康、欧琳等也有较好表现。 我们认为当前市 场主线与科技发展密切相关，主要有三条投资主线：第一是创新药物，这一领 域预计将继续演绎龙头企业的行情；第二是 AI 医疗，上周检验板块有所回调， 但华为组建医疗卫生军团可能会带动新一波上涨；第三是一季报业绩较好的公 • 市场主线与科技发展紧密相关，创新 ...

奥赛康 20250304 摘要 • 奥赛康在经历集采出清期后，2024 年实现经营拐点，全年收入预计增长 20%以上，利润达到 1.7 亿元，扭亏为盈。公司四大业务板块中，消化、 抗感染、慢病和肿瘤领域均呈现增长态势，其中改良型新药和注射用多黏 菌素等产品贡献显著。 • 公司三代 EGFR 抑制剂已获批非小细胞肺癌二线治疗，一线治疗预计近期 获批并进入医保谈判，市场潜力巨大。昆仑 18.2 单抗联合 PD-1 及化疗一 线治疗晚期胃癌，预计 2025 年底完成三期入组，市场渗透率可达 30%， 对应 30 亿市场规模。 • 麦芽酚铁预计 2026 年获批，销售峰值可能达到 10 亿元；眼科双抗对标 罗氏产品，有望优化疗效和给药频次，目前处于临床三期阶段。多黏菌素、 艾沙康唑等新品将在 2025 年及之后贡献显著业绩增量。 • 奥赛康眼科双抗产品针对 VEGFA 和 ANG-2 靶点，采用双价结合方式，结 合能力更强，有望实现更长的给药间隔，提高患者依从性，值得重点关注。 • 公司基于遮蔽探针技术开发的白介素 15 前药作为免疫激活剂，有望成为 现象级品种，目前正处于一期临床阶段。该技术解决了传统细胞因子半衰 ...